Androgen deprivation therapy and cardiovascular harm: Are all men created equal?

摘要

In this month's European Urology, Albertsen and colleagues [1 ] compare cardiovascular (CV) events in men on androgen deprivation therapy (ADT)-either gonadotropin-releasing hormone (GnRH) antagonists or GnRH agonists-n a post hoc analysis of adverse event data pooled from six randomised trials. Among men with preexisting CV disease a (greater than) 50% reduction in the risk of CV events with GnRH antagonist treatment compared with GnRH agonist treatment was observed. The original studies included a variable proportion of men for whom indications for ADT were not clear, including men with localised prostate cancer (PCa) alone. Nevertheless, these results raise some interesting questions.